FDA grants clearance to BioStable’s annuloplasty device for aortic valve

The US Food and Drug Administration (FDA) has granted market clearance to cardiovascular devices firm BioStable Science and Engineering’s HAART 200 Aortic Annuloplasty Device.

Free Report

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.

By GlobalData

By clicking the Download Free Report button, you accept the terms and conditions and acknowledge that your data will be used as described in the GlobalData privacy policy

By downloading this Report, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Developed for bicuspid aortic valve (BAV) repair, the HAART 200 device targets patients with aortic valve insufficiency caused due to BAV.

BAV is a congenital malformation that occurs when aortic valve forms only two functional valve leaflets and is said to result in cardiovascular complications such as aneurysms and aorta dissections.

The majority of BAV patients are reported to require aortic valve replacement, which increases the risk for reoperation or related complications.

Aortic valve repair is intended to act as a surgical alternative to such patients and is expected to improve outcomes when compared to valve replacement.

"HAART 200 is uniquely designed to address the specific technical challenges of BAV repair."

The HAART 200 Aortic Annuloplasty Device is developed to minimise annular diameter based on leaflet size, conform the annulus to a circular symmetric shape for improved valve function, and for providing long-term stabilisation to the annular geometry.

BioStable Science and Engineering president and CEO John Wheeler said: “Valve repair is an especially attractive alternative for the young population of patients requiring surgical intervention for BAV disease.

“HAART 200 is uniquely designed to address the specific technical challenges of BAV repair.”

The firm also previously obtained FDA clearance for its HAART 300 Aortic Annuloplasty Device designed to minimise annular dilatation, restore three-dimensional annular geometry and act as a framework for leaflet repair procedure guidance.

Image: HAART 200 Aortic Annuloplasty Device. Photo: courtesy of BioStable Science and Engineering.